Rex Bionics raises tens of millions of yuan to expand rehab robots globally
What's the deal? Rex BionicsDealroom has a profile for this one. Try Dealroom →, a Wuxi-based maker of rehabilitation robots, has raised tens of millions of yuan in a strategic round. The round was led by Huada Songhe — a tie-up of BGI and Songhe Capital — with existing investor Meian Innovation joining.
What's the endgame? The company builds exoskeletons that help patients recover physical function and regain mobility. Its self-balancing exoskeleton lets wearers stand, sit, squat, and walk without a harness or frame, carrying real neural signals between brain and limbs rather than moving for the patient.
What the money is for: Rex Bionics will fund global commercialisation and product development, with a focus on clinical and health-economics studies in the US and Europe. Its self-balancing exoskeleton already holds EU CE and US FDA certification and has treated patients with neurological conditions abroad.
The company is building two brands: Rex Bionics for in-hospital rehabilitation of neural-injury patients, and Free Future for post-discharge and home-based recovery. It is also developing bedside, walking-assist, and laser therapy robots.
Why now? Rehabilitation and exoskeleton robotics is drawing steady investor interest in China. Shenzhen's MaiBu Robotics raised nearly US$13.8M in August 2026, and Hangzhou's RoboCT raised more than US$13.8M in March to expand R&D and its consumer exoskeleton business.
The signal: Backing from BGI and Songhe Capital lends weight to an early-stage bet in a crowded field. But funding alone does not prove clinical adoption or commercial traction — that will hinge on regulatory progress, clinical evidence, and deployment in the markets Rex Bionics is targeting.
Read more: sohu.com
Image credit: "New Fort Bragg Troop & Family Medical Clinic" by Fort Bragg, licensed under CC BY-ND 2.0